ImmunoCellular Therapeutics Ltd (IMUC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ImmunoCellular Therapeutics Ltd (IMUC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10026
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product pipeline comprises ICT-107, ICT-140 and ICT-121. ICT-107, the lead product candidate of the company is being developed for the treatment of glioblastoma multiforme (GBM); ICT-140, a DC vaccine designed to treat recurrent ovarian cancer; and ICT-121 for the treatment of recurrent GBM and other solid tumors. The company also develops stem cell therapies for treating cancer. As of March 2015, the development of ICT-140 has been put on hold. IMCU is headquartered in Calabasas, California, the US.

ImmunoCellular Therapeutics Ltd (IMUC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
ImmunoCellular Therapeutics to Enter into Agreement with Memgen 13
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 14
ImmunoCellular Therapeutics Enters into Research Agreement with University of Maryland, Baltimore 15
ImmunoCellular Therapeutics Enters into Agreement with Canadian Brain Tumour Consortium 16
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 17
ImmunoCellular Therapeutics Enters into Agreement with Pure MHC 18
Licensing Agreements 19
ImmunoCellular Therapeutics Enters into Licensing Agreement with California Institute of Technology 19
ImmunoCellular Enters Into Licensing Agreement With University of Pittsburgh 20
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 21
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 22
Equity Offering 23
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 23
ImmunoCellular Therapeutics Files for Rights Offering 25
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 26
ImmunoCellular Plans to Raise Funds through Public Offering of Shares 28
ImmunoCellular Therapeutics Raises USD16 Million in Public Offering of Shares and Warrants 29
ImmunoCellular Therapeutics Decreases Size Of Public Offering Of Shares For US$17 Million 30
ImmunoCellular Therapeutics Completes Public Offering Of Shares For US$21 Million 31
ImmunoCellular Therapeutics Completes Public Offering Of Units For US$10.4 Million 33
ImmunoCellular Therapeutics Ltd – Key Competitors 34
ImmunoCellular Therapeutics Ltd – Key Employees 35
ImmunoCellular Therapeutics Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Financial Announcements 37
Aug 13, 2018: ImmunoCellular Therapeutics provides corporate update and reports second quarter 2018 financial results 37
May 14, 2018: ImmunoCellular Therapeutics Reports First Quarter 2018 Financial Results 39
Mar 13, 2018: ImmunoCellular Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results 40
Nov 21, 2017: ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results 41
Aug 14, 2017: ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results 42
May 15, 2017: ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results 43
Mar 09, 2017: ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 44
Product News 46
12/13/2017: ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program 46
Apr 12, 2018: ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program 47
Other Significant Developments 48
Feb 13, 2018: ImmunoCellular Therapeutics Announces Update on Financial Condition 48
Aug 23, 2017: ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoCellular Therapeutics to Enter into Agreement with Memgen 13
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 14
ImmunoCellular Therapeutics Enters into Research Agreement with University of Maryland, Baltimore 15
ImmunoCellular Therapeutics Enters into Agreement with Canadian Brain Tumour Consortium 16
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 17
ImmunoCellular Therapeutics Enters into Agreement with Pure MHC 18
ImmunoCellular Therapeutics Enters into Licensing Agreement with California Institute of Technology 19
ImmunoCellular Enters Into Licensing Agreement With University of Pittsburgh 20
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 21
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 22
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 23
ImmunoCellular Therapeutics Files for Rights Offering 25
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 26
ImmunoCellular Plans to Raise Funds through Public Offering of Shares 28
ImmunoCellular Therapeutics Raises USD16 Million in Public Offering of Shares and Warrants 29
ImmunoCellular Therapeutics Decreases Size Of Public Offering Of Shares For US$17 Million 30
ImmunoCellular Therapeutics Completes Public Offering Of Shares For US$21 Million 31
ImmunoCellular Therapeutics Completes Public Offering Of Units For US$10.4 Million 33
ImmunoCellular Therapeutics Ltd, Key Competitors 34
ImmunoCellular Therapeutics Ltd, Key Employees 35
ImmunoCellular Therapeutics Ltd, Subsidiaries 36
ImmunoCellular Therapeutics Ltd, Joint Venture 36

List of Figures
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ImmunoCellular Therapeutics Ltd (IMUC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Capsugel Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Capsugel Inc (Capsugel) is a contract manufacturing company which designs, develops and manufactures a range of innovative dosage forms. It provides contract services to the biopharmaceutical and consumer health and nutrition industries. The company’s services enable clients to enhance the b …
  • Profectus BioSciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Profectus BioSciences Inc (Profectus) is a clinical-stage vaccine development company that designs and develops preventive and therapeutic vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy. The company's products include genevax therapeutic vaccines, vesiculova …
  • Far Eastone Telecommunications Co Ltd (4904):企業の財務・戦略的SWOT分析
    Far Eastone Telecommunications Co Ltd (4904) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Monopar Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Monopar Therapeutics LLC (Monopar) is a biopharmaceutical company that develops orphan oncology compounds. The company’s pipeline product include huATN-658, a humanized monoclonal antibody for the potential treatment of various cancers including pancreatic cancer, ovarian cancer, and others. …
  • Plantronics, Inc. (PLT):企業の財務・戦略的SWOT分析
    Plantronics, Inc. (PLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • AbbVie Inc.:企業の戦略・SWOT・財務情報
    AbbVie Inc. - Strategy, SWOT and Corporate Finance Report Summary AbbVie Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Zimmer Biomet Holdings Inc (ZBH):企業の財務・戦略的SWOT分析
    Zimmer Biomet Holdings Inc (ZBH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • The Yokohama Rubber Co., Ltd.:企業の戦略・SWOT・財務情報
    The Yokohama Rubber Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Yokohama Rubber Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Avista Corporation
    Avista Corporation - Strategy, SWOT and Corporate Finance Report Summary Avista Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Anthem Inc (ANTM):企業の財務・戦略的SWOT分析
    Anthem Inc (ANTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Nova Eye Medical Ltd (EYE):企業の財務・戦略的SWOT分析
    Nova Eye Medical Ltd (EYE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Texas Instruments Incorporated (TXN):医療機器:M&Aディール及び事業提携情報
    Summary Texas Instruments Incorporated (TI) designs and manufactures and sells semiconductors to electronics designers and manufacturers the world over. It offers catalog and application-specific standard semiconductor products through its analog chips and embedded processors divisions. Its analog c …
  • ShotSpotter Inc (SSTI):企業の財務・戦略的SWOT分析
    ShotSpotter Inc (SSTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Dolby Laboratories Inc (DLB):企業の財務・戦略的SWOT分析
    Dolby Laboratories Inc (DLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Vietnam National Petroleum Group (PLX):企業の財務・戦略的SWOT分析
    Vietnam National Petroleum Group (PLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Israel Aerospace Industries Ltd:戦略・SWOT・企業財務分析
    Israel Aerospace Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Israel Aerospace Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Vattenfall AB:企業の戦略的SWOT分析
    Vattenfall AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • China Unicom (Hong Kong) Limited:企業の戦略・SWOT・財務情報
    China Unicom (Hong Kong) Limited - Strategy, SWOT and Corporate Finance Report Summary China Unicom (Hong Kong) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Personal Genome Diagnostics Inc:製品パイプライン分析
    Summary Personal Genome Diagnostics Inc (PGD) is a genomic solution provider. The company develops next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. It provides a portfolio of regulated tissue-based and liquid biopsy genomic products for laborat …
  • Davisco Foods International, Inc.:戦略・SWOT・企業財務分析
    Davisco Foods International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Davisco Foods International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆